AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...
Panelists highlight that menin inhibitors represent a breakthrough in the treatment of KMT2A-rearranged AML by targeting the disease’s core epigenetic drivers, with early clinical trials like ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results